antisoma plc cancer drug developed with novartis fails trial antisoma plc of the united kingdom said an experimental drug it is developing with switzerlands novartis ag failed in a midstage clinical trial for ovarian cancer antisoma said data found its asa drug didnt raise the median time to tumor progression antisoma shares were down to pence cents in london yesterday antisoma licensed asa to novartis in april previous trials showed the drug increased median survival when added with chemotherapy in nonsmall cell lung cancer novartis shares fell less than to &# in p m new york stock exchange composite trading novartis plans to enroll patients in a trial for the compound in other tumors 
